 This is an open-label both physician and participant know the treatment that the participant receives, randomized study medication is assigned by chance, multicenter clinical study assessing the safety of the combination of rivaroxaban and ticagrel versus triple antithrombotic regimen warfarin, clopigogrel and aspirin in patients, who have paroxysmal, persistent, or permanent non-valvular atrial fibrillation AF and concomitant coronary artery disease undergoing percutaneous coronary intervention PCI. A target of 420 participants will be randomized into the study, with approximately 210 participants in each treatment strategy group. Primary comparisons will be made of the rates of major and clinically relevant bleeding, assessed by the modified International Society of Thrombosis and Haemostasis ISTH classification. The study consists of a screening phase, a 12-month open-label treatment phase, and an end-of-treatmentearly withdrawal visit. The total duration of participation in the study for each participant is approximately 12 months. 